(68)Ga-prostate-specific membrane antigen (PSMA) and (68)Ga-DOTA0-Tyr3-octreotate (DOTATATE) positron emission tomography/computed tomography (PET/CT) in a case of metastatic castration-resistant prostate cancer (mCRPC) with low prostate-specific antigen (PSA) and reduced (18)F-fluorodeoxyglucose (FDG) uptake after endocrine therapy

在一例转移性去势抵抗性前列腺癌（mCRPC）患者中，采用（68）Ga-前列腺特异性膜抗原（PSMA）和（68）Ga-DOTA0-Tyr3-奥曲肽（DOTATATE）正电子发射断层扫描/计算机断层扫描（PET/CT）检测前列腺特异性抗原（PSMA）和（68）Ga-DOTA0-Tyr3-奥曲肽（DOTATATE）的显像结果。该患者在接受内分泌治疗后，前列腺特异性抗原（PSA）水平较低，且（18）F-氟代脱氧葡萄糖（FDG）摄取减少。